Ashland Narrows Q1 Loss, Revises Full-Year Guidance

Ashland Inc. (NYSE: ASH) reported a narrower-than-expected loss for fiscal Q1 2026, driven by improved margins in its life sciences and personal care segments. The company also updated its full-year outlook, citing resilient demand and ongoing cost optimization. The specialty materials firm posted an adjusted loss of $0.18 per share, compared to a $0.34 loss in the prior-year quarter, beating analyst estimates. Revenue fell 4% year-over-year to $582 million, slightly below consensus. Ashland now expects full-year adjusted EBITDA between $375 million and $400 million, up from its previous range of $350 million to $385 million, reflecting stronger operational performance and lower input costs.